Lucentis
E46708
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
Aliases (1)
- ranibizumab ×1
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anti-VEGF agent
→
biologic drug → ophthalmic drug → prescription medicine → |
| approvedBy |
European Medicines Agency
→
U.S. Food and Drug Administration → |
| belongsToRegulatoryCategory |
prescription-only medicine
→
|
| contraindicatedIn |
known hypersensitivity to ranibizumab
→
ocular or periocular infection → |
| developedBy |
Genentech
→
Roche → |
| hasAdministrationFrequency |
monthly in many regimens
→
|
| hasAdministrationPattern |
treat-and-extend regimens may be used
→
|
| hasApprovalYear |
2006
→
|
| hasATCCode |
S01LA04
→
|
| hasCommonAdverseEffect |
conjunctival hemorrhage
→
eye pain → increased intraocular pressure → |
| hasDosageForm |
solution for injection
→
|
| hasDrugClass |
monoclonal antibody fragment
→
vascular endothelial growth factor inhibitor → |
| hasGenericName |
ranibizumab
→
|
| hasIndicationType |
treatment of choroidal neovascularization
→
vision preservation → |
| hasMolecularType |
humanized monoclonal antibody fragment
→
|
| hasRouteOfAdministration |
intravitreal injection
→
|
| hasSeriousAdverseEffect |
endophthalmitis
→
retinal detachment → |
| hasTherapeuticArea |
ophthalmology
→
|
| hasTherapeuticGoal |
improve visual acuity
→
slow progression of vision loss → |
| isAdministeredBy |
ophthalmologist
→
|
| isRelatedDrug |
aflibercept
→
bevacizumab → faricimab → |
| isUsedFor |
diabetic macular edema
→
diabetic retinopathy → macular edema following retinal vein occlusion → myopic choroidal neovascularization → neovascular age-related macular degeneration → wet age-related macular degeneration → |
| marketedBy |
Genentech
→
Novartis → |
| mechanismOfAction |
inhibits VEGF-A
→
reduces abnormal blood vessel growth in the retina → reduces vascular permeability in the retina → |
| targets |
vascular endothelial growth factor A
→
|
| treatsAnatomicalSite |
macula
→
retina → |
Referenced by (2)
| Subject (surface form when different) | Predicate |
|---|---|
|
Lucentis
("ranibizumab")
→
|
hasGenericName |
|
Genentech
→
|
notableProduct |